- Home
- WYHG vs LUNG Comparison
WYHG vs LUNG Comparison
Compare WYHG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- LUNG
- Stock Information
- Founded
- WYHG 1915
- LUNG 1995
- Country
- WYHG China
- LUNG United States
- Employees
- WYHG 491
- LUNG N/A
- Industry
- WYHG
- LUNG Industrial Specialties
- Sector
- WYHG
- LUNG Health Care
- Exchange
- WYHG NYSE
- LUNG Nasdaq
- Market Cap
- WYHG 261.7M
- LUNG 256.3M
- IPO Year
- WYHG 2024
- LUNG 2020
- Fundamental
- Price
- WYHG $8.04
- LUNG $5.91
- Analyst Decision
- WYHG
- LUNG Buy
- Analyst Count
- WYHG 0
- LUNG 6
- Target Price
- WYHG N/A
- LUNG $11.92
- AVG Volume (30 Days)
- WYHG 353.7K
- LUNG 224.4K
- Earning Date
- WYHG 01-01-0001
- LUNG 02-19-2025
- Dividend Yield
- WYHG N/A
- LUNG N/A
- EPS Growth
- WYHG 10.09
- LUNG N/A
- EPS
- WYHG 0.27
- LUNG N/A
- Revenue
- WYHG $144,231,605.00
- LUNG $79,302,000.00
- Revenue This Year
- WYHG N/A
- LUNG $22.26
- Revenue Next Year
- WYHG N/A
- LUNG $18.72
- P/E Ratio
- WYHG $5.05
- LUNG N/A
- Revenue Growth
- WYHG 9.73
- LUNG 22.34
- 52 Week Low
- WYHG $3.55
- LUNG $5.46
- 52 Week High
- WYHG $5.35
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- LUNG 40.07
- Support Level
- WYHG N/A
- LUNG $5.92
- Resistance Level
- WYHG N/A
- LUNG $6.40
- Average True Range (ATR)
- WYHG 0.00
- LUNG 0.35
- MACD
- WYHG 0.00
- LUNG -0.07
- Stochastic Oscillator
- WYHG 0.00
- LUNG 15.88
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The company is mainly engaged in offering ready to eat and packaged meat dishes. Its product offerings include supreme crispy sausage, fully thin sausage, Chinese sausage, Dongguan Erba sausage, yellow scorpion sausage, alcohol sausage, and meat chop.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.